CA2538104C - Use of xenon with hypothermia for treating neonatal asphyxia - Google Patents

Use of xenon with hypothermia for treating neonatal asphyxia Download PDF

Info

Publication number
CA2538104C
CA2538104C CA2538104A CA2538104A CA2538104C CA 2538104 C CA2538104 C CA 2538104C CA 2538104 A CA2538104 A CA 2538104A CA 2538104 A CA2538104 A CA 2538104A CA 2538104 C CA2538104 C CA 2538104C
Authority
CA
Canada
Prior art keywords
xenon
use according
hypothermia
administration
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2538104A
Other languages
English (en)
French (fr)
Other versions
CA2538104A1 (en
Inventor
Nicholas Peter Franks
Mervyn Maze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Protexeon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34436835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2538104(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0323861A external-priority patent/GB0323861D0/en
Priority claimed from GB0418539A external-priority patent/GB0418539D0/en
Application filed by Protexeon Ltd filed Critical Protexeon Ltd
Publication of CA2538104A1 publication Critical patent/CA2538104A1/en
Application granted granted Critical
Publication of CA2538104C publication Critical patent/CA2538104C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CA2538104A 2003-10-10 2004-10-11 Use of xenon with hypothermia for treating neonatal asphyxia Expired - Fee Related CA2538104C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0323861.5 2003-10-10
GB0323861A GB0323861D0 (en) 2003-10-10 2003-10-10 Use
GB0418539.3 2004-08-19
GB0418539A GB0418539D0 (en) 2004-08-19 2004-08-19 Use
PCT/GB2004/004298 WO2005034966A1 (en) 2003-10-10 2004-10-11 Use of xenon with hypothermia for treating neonatal asphyxia

Publications (2)

Publication Number Publication Date
CA2538104A1 CA2538104A1 (en) 2005-04-21
CA2538104C true CA2538104C (en) 2013-12-10

Family

ID=34436835

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2538104A Expired - Fee Related CA2538104C (en) 2003-10-10 2004-10-11 Use of xenon with hypothermia for treating neonatal asphyxia

Country Status (13)

Country Link
US (1) US7390508B2 (enExample)
EP (1) EP1670489B1 (enExample)
JP (1) JP4880466B2 (enExample)
AT (1) ATE380554T1 (enExample)
AU (1) AU2004280118B2 (enExample)
BR (1) BRPI0415232A (enExample)
CA (1) CA2538104C (enExample)
DE (1) DE602004010691T2 (enExample)
DK (1) DK1670489T3 (enExample)
ES (1) ES2298815T3 (enExample)
MX (1) MXPA06003471A (enExample)
PT (1) PT1670489E (enExample)
WO (1) WO2005034966A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2538104C (en) * 2003-10-10 2013-12-10 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia
GB0418540D0 (en) 2004-08-19 2004-09-22 Protexeon Ltd Use
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
ITMI20071031A1 (it) * 2007-05-22 2008-11-23 Acetilene & Deriv Ati Siad Spa Uso di xenon per la protezione di organi da danno ischemico
AU2014277860A1 (en) * 2008-01-22 2015-01-22 Board Of Regents, The University Of Texas System Volatile anesthetic compositions and methods of use
US20110159078A1 (en) * 2008-01-22 2011-06-30 Vapogenix, Inc Volatile Anesthetic Compositions and Methods of Use
EP3195896A1 (en) * 2009-05-05 2017-07-26 Board of Regents, The University of Texas System Novel formulations of volatile anesthetics and methods of use for reducing inflammation
CN110464709A (zh) 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法
CN110354067A (zh) 2013-03-15 2019-10-22 德克萨斯州大学系统董事会 富含稀有气体的液体及其制备和使用方法
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
JP6622822B2 (ja) 2015-06-23 2019-12-18 ノビリス セラピューティクス インコーポレイテッド 希ガス組成物を用いた治療的な免疫調節
US10022397B2 (en) * 2016-06-20 2018-07-17 Nobilis Therapeutics, Inc. Treatment of rheumatoid arthritis using noble gas mixtures

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099834A (en) * 1991-07-16 1992-03-31 Union Carbide Industrial Gases Technology Corporation Method for anesthesia
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
DE19910986C2 (de) * 1999-03-11 2001-06-07 Aga Ab Verwendung von Xenon bei der Behandlung von Neurointoxikationen
DE19933704A1 (de) * 1999-07-19 2001-01-25 Michael Georgieff Verwendung einer lipophile Gase enthaltenden Präparation zur Neuroprotektion und Neuroregeneration
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
US6653354B2 (en) * 1999-07-29 2003-11-25 Protexeon Limited NMDA antagonist comprising xenon
WO2001078580A2 (en) * 2000-03-31 2001-10-25 Innercool Therapies, Inc. A method combining inducing hypothermia and administering a therapeutic agent
CA2538104C (en) * 2003-10-10 2013-12-10 Protexeon Limited Use of xenon with hypothermia for treating neonatal asphyxia

Also Published As

Publication number Publication date
DE602004010691T2 (de) 2008-12-04
AU2004280118A1 (en) 2005-04-21
EP1670489A1 (en) 2006-06-21
EP1670489B1 (en) 2007-12-12
BRPI0415232A (pt) 2006-12-12
US7390508B2 (en) 2008-06-24
DK1670489T3 (da) 2008-01-07
JP4880466B2 (ja) 2012-02-22
AU2004280118B2 (en) 2009-01-15
WO2005034966A1 (en) 2005-04-21
US20070104796A1 (en) 2007-05-10
DE602004010691D1 (de) 2008-01-24
MXPA06003471A (es) 2006-06-14
CA2538104A1 (en) 2005-04-21
ATE380554T1 (de) 2007-12-15
PT1670489E (pt) 2008-02-28
ES2298815T3 (es) 2008-05-16
JP2007508284A (ja) 2007-04-05

Similar Documents

Publication Publication Date Title
JP4598203B2 (ja) 脳機能改善剤
CA2538104C (en) Use of xenon with hypothermia for treating neonatal asphyxia
DE69737510T2 (de) Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
Farias et al. Prevention of ischemic-hypoxic brain injury and death in rabbits with fructose-1, 6-diphosphate.
DE69533190T2 (de) Behandlung von pulmonaler vasokonstriktion und asthma
DE69511279T2 (de) Verwendung von flüssigen fluorcarbonen zur förderung der arzneistoffabgabe an den lungen
US20150216897A1 (en) Use of xenon as neuroprotectant in a neonatal subject
Lawson et al. Corticosteroids as treatment for aspiration of gastric contents: An experimental study
Luisada Therapy of paroxysmal pulmonary edema by antifoaming agents
AU2003227896B2 (en) Use of xenon for the control of neurological deficits associated with cardiopulmonary bypass
DE60318453T2 (de) Analgetikum für neugeborene und föten
DE60022070T2 (de) Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen
Lucas Anoxia and anaesthesia
Kross et al. No dantrolene protection in a dog model of complete cerebral ischaemia
Von Oettingen Toxicity and potential dangers of aliphatic and aromatic hydrocarbons: a critical review of the literature
Oenbrink Unexpected adverse effects of Freon 11 and Freon 12 as medication propellants
Ngai Halothane
Giri et al. Effect of dactinomycin and ethionine on thiourea and phenylthiourea tolerance
Pierce Oxygen: A drug
CH549006A (de) Verfahren zur herstellung von (alpha)-pinenoxyd.
Chaudry Circulatory Shock. Volume 27, Number 4, 1989

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20201013